Current guidelines in melanoma treatment

Dermatology

Volumn 200, Issue 2, 2000, Pages 160-166

  Brochez, L ^a,b   Verhaeghe, E ^a,b   Sales, F ^c   Del Marmol, V ^c   Deraemaecker, R ^c   Vossaert, K ^a   Naeyaert, Jean Marie ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b RESEARCH FOUNDATION FLANDERS FWO   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

Author keywords

Immunotherapy; Interferon; Melanoma; Staging system; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; DACARBAZINE; GANGLIOSIDE GM2; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; FOLLOW UP; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TUMOR BIOPSY; VACCINATION;

EID: 0034109098     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000018356     Document Type: Review

References (22)

1. Ketcham AS, Moffat FL, Balch CM: Classification and staging; in Balch CM, Houghton A, Milton G, Sober A, Soong S (eds): Cutaneous Melanoma. Philadelphia, Lippincott, 1992, pp 213-220.
2. Buzaid AC, Ross MI, Balch CM, Soong S, McCarthy WH, Tinoco L, Mansfield P, Lee JE, Bedikian A, Eton O, Plager C, Papadopoulos N, Legha SS, Benjamin RS: Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997;15:1039-1051.
3. Balch CM, Soong SJ, Shaw HM, Urist MM, McCarthy WH: An analysis of prognostic factors in 8,500 patients with cutaneous melanoma; in Balch CM, Houghton A, Milton G, Sober A, Soong S (eds): Cutaneous Melanoma. Philadelphia, Lippincott, 1992, pp 165-187.
4. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng C, Lee JJ, Balch CM, Reintgen DS, Ross MI: Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stages I and II melanoma patients. J Clin Oncol 1999;17:976-983.
5. Garbe C, et al: Primary cutaneous melanoma: Prognostic classification of anatomic location. Cancer 1995;75:2492-2498.
6. Miller JG, MacNeil S: Gender and cutaneous melanoma. Br J Dermatol 1997;136:657-665.
7. Austin PF, Cruse CW, Lyman G, Schroer K, Glass F, Reintgen DS: Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol 1994;1:487-494.
8. Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, Jewell WR, Bartolucci AA, Mihm MC, Barnhill R, Wanebo HJ: Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4mm): Ann Surg 1993;218:262-269.
9. Ringborg U, Andersson R, Eldh J, Glaumann B, Hafström L, Jacobsson S, Jönsson PE, Johansson H, Krysander L, Lagerlöf B, Swedish Melanoma Study Group: Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with tumor thickness of 0.8 to 2.0 cm. Cancer 1996;77:1809-1814.
10. Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Ross MI, Jewell WR, Mihm MC, Barnhill RL, Wanebo HJ: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-266.
11. Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N, Claudio F, Ikonopisov RL, Javorskj VV, Kirov S, Kulakowski A, Lacoub J, Lejeune F, Mechl Z, Morabito A, Rode I, Sergeev S, van Slooten E, Szcygiel K, Trapeznikov NN: Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977;297:627-630.
12. Sim FH, Taylor WF, Pritchard DJ, Soule EH: Lymphadenectomy in the management of stage I malignant melanoma: A prospective randomized study. Mayo Clin Proc 1986;61: 697-705.
13. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F: Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomized trial-WHO Melanoma Programme. Lancet 1998;14: 793-796.
14. Glass FL, Coltam JA, Reintgen DS, Fenske NA: Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma. J Am Acad Dermatol 1998;39:603-610.
15. Morton DL: Sentinel lymphadenectomy for patients with clinical stage I melanoma. J Surg Oncol 1997;66:267-269.
16. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399.
17. Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, Eggermont AM, Di Filippo F, Krementz ET, Ruiter D, Lejeune FJ: Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998;16:2906-2912.
18. Wong JH, Skinner KA, Kim KA, Foshag LJ, Morton DL: The role of surgery in the treatment of nonregionally recurrent melanoma. Surgery 1993;113:389-394.
19. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
20. Livingston PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G, et al: Improved survival in stage III melanoma patients with GM2 antibodies: A randomised trial of adjuvant vaccination with GM2 gangliosides. J Clin Oncol 1994;12:1036-1044.
21. Demierre MF, Koh HK: Adjuvant therapy for cutaneous malignant melanoma. J Am Acad Dermatol 1997;36:747-764.
22. Schmidt-Ulrich RK, Johnson CR: Role of radiotherapy and hypothermia in the management of malignant melanoma. Semin Surg Oncol 1996;12:407-415.